Does GEHA Cover Weight Loss Medication? 2026 Tiers and Costs

Yes. For the 2026 plan year, GEHA covers four weight loss medications: generic liraglutide, Wegovy, Saxenda, and Zepbound. Every one of them requires prior authorization or a formulary exception before the plan pays, and a formulary change that took effect January 1, 2026 raised out-of-pocket costs for most members. What you actually pay depends on which GEHA plan you’re enrolled in.

Which Weight Loss Drugs GEHA Covers

GEHA’s pharmacy benefit is administered through CVS Caremark. Four weight loss medications appear on the formulary for 2026:

  • Generic liraglutide is classified as a generic across all GEHA plans. Prior authorization is required.
  • Wegovy (semaglutide) is covered with prior authorization. It is a preferred medication on the Elevate plan and non-preferred on the High, Standard, HDHP, and Elevate Plus plans.
  • Saxenda (liraglutide) follows the same pattern as Wegovy: preferred on Elevate, non-preferred on all other plans. Prior authorization is required.
  • Zepbound (tirzepatide) is non-formulary on every GEHA plan. It can still be covered, but through an approved formulary exception rather than a standard prior authorization.

Ozempic and Mounjaro are not listed on GEHA’s weight loss formulary documents. Both are FDA-approved for type 2 diabetes, and while they are sometimes prescribed off-label for weight loss, they do not appear in GEHA’s weight loss coverage.

The January 2026 Tier Change

On January 1, 2026, GEHA reclassified Wegovy and Saxenda from preferred to non-preferred for members on the High, Standard, HDHP, and Elevate Plus plans. The drugs are still covered, but at a higher cost-sharing tier. GEHA has stated that out-of-pocket costs for affected members “may change” as a result.

If you’re on the Elevate plan, nothing changed. Wegovy and Saxenda remain preferred under Elevate for 2026.

What You’ll Pay

Costs depend on your plan and the tier your drug sits in.

On the High plan, a 30-day retail supply of a preferred brand-name drug costs 25% coinsurance, capped at $250 per fill. A non-preferred brand-name drug on the same plan costs 40% coinsurance, capped at $400 per fill. For 90-day mail-order supplies, the caps rise to $500 for preferred and $800 for non-preferred brands. Because Wegovy and Saxenda are now non-preferred on the High plan, most members fall into the higher tier.

On the Elevate plan, where Wegovy and Saxenda remain preferred, members pay 50% coinsurance on preferred brand drugs, capped at $500 per fill for a 30-day retail supply. Prescription drug costs on Elevate are not subject to a deductible.

The HDHP works differently. You generally must meet the annual deductible ($1,800 for self-only coverage in 2026) before the plan pays its share of prescription drug costs. After the deductible, coinsurance of 25% to 40% applies depending on tier.

For a personalized estimate, GEHA directs members to the “Check Drug Costs” tool through CVS Caremark, or to call CVS Caremark at 1-844-443-4279.

Prior Authorization: What You Need to Qualify

Every weight loss medication on GEHA’s formulary requires prior authorization, which is a clinical review confirming the prescription is medically appropriate. CVS Caremark publishes the criteria.

For adults seeking Wegovy, the clinical requirements include:

  • Participation in a comprehensive weight management program with behavioral modification, a reduced-calorie diet, and increased physical activity, with continuing follow-up, for at least six months before starting the medication.
  • A BMI of 30 or higher, which qualifies on its own; or a BMI between 27 and 30 with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.
  • Documentation of baseline BMI and any weight-related comorbid conditions.

Initial approval lasts seven months for the injection or six months for the tablet form. To continue therapy, adults must show at least a 5% reduction in baseline body weight, or maintenance of an initial 5% loss, after at least three months at a stable maintenance dose. Continuation approvals then run for 12 months. Adolescents aged 12 to 17 have a parallel pathway for injectable Wegovy that requires the same six-month program and a baseline BMI at or above the 95th percentile for age and sex.

Getting Zepbound Covered

Because Zepbound is non-formulary on every GEHA plan, it needs a formulary exception rather than a standard prior authorization. The review is more stringent. CVS Caremark evaluates whether the medication is clinically appropriate, safe, and affordable, and whether any formulary medications would work for the member instead.

You or your provider can submit a Formulary Exception/Prior Authorization Request Form through the GEHA website. Providers can start the process in advance. If the exception is approved, Zepbound is treated as a covered medication.

If Your Request Is Denied

GEHA members can appeal a denial through a multi-level process. The first step is an initial appeal to GEHA, submitted within six months of the denial. If GEHA upholds the denial, you can request a second-level reconsideration, during which GEHA may consult a health care professional. If you still disagree, you can request a review by the Office of Personnel Management, which issues a final decision within 60 days.

Appeals can be submitted by mail, fax, or email. Post-service appeals go to GEHA Post-Service Appeals, P.O. Box 21324, Eagan, MN 55121. Pre-service appeals go to P.O. Box 400046, San Antonio, TX 78229. The fax number is 1-866-963-0156, and the appeals email address is gehaappeals@geha.com. Status is available through the MyGEHA portal or by calling Customer Care at 1-877-445-5643.

Bariatric Surgery and Weight Loss Programs

GEHA’s FEHB plans cover bariatric surgery as a listed benefit under “Other Covered Services” for 2026. The plans explicitly exclude “weight loss programs,” which GEHA treats as a separate category from both prescription medications and surgical procedures. Full terms, limitations, and any pre-authorization requirements for bariatric surgery appear in each plan’s FEHB brochure.

Medicare-Eligible Retirees

If you’re a federal retiree with Medicare, the picture is different. GEHA’s Medicare prescription drug plan is administered through SilverScript Insurance Company, affiliated with CVS Caremark, and includes a $2,100 annual out-of-pocket maximum on Part D medications.

A Medicare GLP-1 Bridge Program launching July 1, 2026 will provide access to Wegovy, Foundayo, and Zepbound KwikPen for eligible Part D beneficiaries, including those in FEHB employer group waiver plans. The copay is $50 per fill, and the program runs through December 31, 2027. Expenses under the Bridge Program do not count toward an FEHB plan’s catastrophic limit, so compare costs carefully before opting in.

Foundayo (orforglipron), an oral GLP-1 that received FDA approval in April 2026, is not currently listed on GEHA’s weight loss formulary documents. CVS Caremark removed its new-to-market block on Foundayo effective June 1, 2026 for plans that approve coverage, but whether GEHA has added it is not confirmed. Call CVS Caremark at 1-844-443-4279 for current information.